cas 23877-12-5|| where to buy tert-Butyl 2-bromoisobutyrate

Product Name:tert-Butyl 2-bromoisobutyrate

IUPAC Name:tert-butyl 2-bromo-2-methylpropanoate

Packing Unit	Available Stock	Price($)
CM361119-500g	in stock	ɐȌ
CM361119-1000g	in stock	ǕȷƱ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 23877-12-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:23877-12-5; Molecular Formula:C8H15BrO2; Melting Point:-; Smiles Code:CC(C)(Br)C(OC(C)(C)C)=O; Density:

: Catalog Number:CM361119; Molecular Weight:223.11; Boiling Point:; MDL No:MFCD00051908; Storage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.